A5111109696- Inflammatory Biomarkers in Disease Prognosis
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- MicroRNA in disease regulation
- Monoclonal and Polyclonal Antibodies Research
- Autophagy in Disease and Therapy
- Biosimilars and Bioanalytical Methods
- Advanced Breast Cancer Therapies
- Histone Deacetylase Inhibitors Research
- Connective tissue disorders research
- Reproductive System and Pregnancy
- PI3K/AKT/mTOR signaling in cancer
- Brain Metastases and Treatment
- Per- and polyfluoroalkyl substances research
- Dermatology and Skin Diseases
- Fibroblast Growth Factor Research
- Uterine Myomas and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Immune cells in cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- Circular RNAs in diseases
- Adipokines, Inflammation, and Metabolic Diseases
Jiangsu T-mab BioPharma (China)
2025
Affiliated Hospital of Nantong University
2024
Nanjing Medical University
2023-2024
Huazhong University of Science and Technology
2024
Tongji Hospital
2024
Tongji University
2024
Shanghai Institute of Pollution Control and Ecological Security
2024
Nantong University
2024
Jiangsu Province Hospital
2023-2024
Nanjing Chest Hospital
2024
This open-label phase II trial (NCT04542837) aimed to evaluate the efficacy and safety of KN046 combined with lenvatinib in patients advanced hepatocellular carcinoma (HCC), explore potential response biomarkers. Participants received 5 mg/kg every 3 weeks 12 or 8 mg once daily. The primary endpoints were safety, tolerability, dose-limiting toxicity (DLT), objective rate (ORR) according RECIST v1.1. A total fifty-five participants enrolled. results meet pre-specified endpoints. No DLT was...
To evaluate the efficacy and safety of KN026, a novel bispecific HER2 (ECD2 ECD4) antibody, plus KN046, PD-L1, CTLA4 in patients with advanced HER2-positive solid tumors. We conducted two sequentially designed phase Ib II studies similar target populations evaluation schedules. The primary endpoints included safety, maximum tolerated dose (MTD), recommended (RP2D) for study, objective response rate (ORR) duration (DoR) study. Hereby, we solely report results from 113 nonbreast cancer...
Abstract Purpose: Here we reported the results from a phase II trial assessing safety and efficacy of KN046 in combination with KN026 HER2-positive metastatic breast cancer patients, who had progressed after prior anti-HER2 therapies. Patients Methods: Female patients were previously treated at least one line HER2-targeted therapy enrolled multiple academic hospitals China to receive (iv. 5 mg/kg Q3W) plus 30 until progression, unacceptable toxicities or patient withdrawal. Efficacy was...
Abstract Background Circular RNAs (circRNAs) are involved in the regulation of progression and drug resistance ovarian cancer (OC). In present study, we aimed to explore role circRAD23B, a newly identified circRNA, carboplatin-resistant OC. Methods CircRAD23B expression levels were measured using qRT-PCR. The biological roles circRAD23B analysed CCK-8, colony formation, EDU, flow cytometry, cell viability assays. RNA pull-down luciferase assays used investigate interactions with mRNAs...
Autophagy exerts a vital role in the progression of lung squamous cell carcinoma (LUSC). Ubiquitin-specific peptidase 31 (USP31) has recently been found to be involved development variety cancers. However, whether USP31 modulates autophagy LUSC remains unclear.
e20555 Background: Leptomeningeal metastasis (LM) is a severe complication of advanced lung adenocarcinoma (LUAD) and always has dismal prognosis. EGFR exon 20 insertion ( 20ins) the third most common mutations; however, there are currently no reports focusing on LM with 20ins, optimal therapy for these patients remains unclear. This retrospective study aimed to evaluate efficacy safety high-dose furmonertinib in combination intraventricular chemotherapy 20ins mutated LUAD LM. Methods:...
With the widespread use of next-generation sequencing (NGS) for solid tumors, mesenchymal-to-epithelial transition factor (MET) rearrangement/fusion has been confirmed in multiple cancer types. MET amplification and exon 14 skipping mutations induce protein autophosphorylation; however, pathogenic mechanism drug sensitivity fusion remain unclear. The following report describes clinical case a patient diagnosed with squamous lung bearing TFG-MET gene fusion. In vitro assays demonstrated...
<title>Abstract</title> <bold>Purpose: </bold>The<bold> </bold>treatment of leptomeningeal metastasis (LM), a serious complication advanced non-small cell lung cancer (NSCLC), presents challenges, particularly in patients with EGFR exon 20 insertion (ex20ins) mutations. <bold>Methods:</bold> This study retrospectively analyzed data from 10 ex20ins-mutated NSCLC LM admitted at our institution May 2011 to June 2023. Circulating tumor DNA (ctDNA) cerebrospinal fluid (CSF) and matched plasma...
Abstract BACKGROUND Oligodendroglia encompass oligodendrocyte precursor cells (OPCs) and oligodendrocytes (OLs). In the grey matter of cortex, nearly all OPCs divide slowly, yet they don’t differentiate solely into mature OLs, leaving exact role these in enigmatic. METHODS Oligodendroglia, including OPCs, were traced using Sox10 Cre-ER T2 reporter mice. We compared effect tamoxifen dissolved different solvents on fate cells. also dosage The differentiation labeled red fluorescent protein...
Abstract Background KN026 is a novel bispecific antibody and simultaneously binds to two distinct HER2 epitopes which are the same domains as trastuzumab (ECD4) pertuzumab (ECD2). It showed higher maximal binding than monospecific antibodies favors that crosslinking of receptors could enhance internalization in preclinical studies. significantly inhibited growth human cancer cell lines demonstrated obviously antitumor activity against different xenografts models. The encouraging efficacy...